These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Topographic correlates of driver mutations and endogenous gene expression in pediatric diffuse midline gliomas and hemispheric high-grade gliomas. Kazarian E; Marks A; Cui J; Darbinyan A; Tong E; Mueller S; Cha S; Aboian MS Sci Rep; 2021 Jul; 11(1):14377. PubMed ID: 34257334 [TBL] [Abstract][Full Text] [Related]
6. Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib. Wang Z; Xu C; Diplas BH; Moure CJ; Chen CJ; Chen LH; Du C; Zhu H; Greer PK; Zhang L; He Y; Waitkus MS; Yan H Mol Cancer Res; 2020 Jul; 18(7):968-980. PubMed ID: 32229503 [TBL] [Abstract][Full Text] [Related]
7. De Novo Truncating Mutations in the Last and Penultimate Exons of PPM1D Cause an Intellectual Disability Syndrome. Jansen S; Geuer S; Pfundt R; Brough R; Ghongane P; Herkert JC; Marco EJ; Willemsen MH; Kleefstra T; Hannibal M; Shieh JT; Lynch SA; Flinter F; FitzPatrick DR; Gardham A; Bernhard B; Ragge N; Newbury-Ecob R; Bernier R; Kvarnung M; Magnusson EA; Wessels MW; van Slegtenhorst MA; Monaghan KG; de Vries P; Veltman JA; ; Lord CJ; Vissers LE; de Vries BB Am J Hum Genet; 2017 Apr; 100(4):650-658. PubMed ID: 28343630 [TBL] [Abstract][Full Text] [Related]
8. Molecular landscape of pediatric diffuse intrinsic pontine gliomas: about 22 cases. El Ayoubi R; Boisselier B; Rousseau A J Neurooncol; 2017 Sep; 134(2):465-467. PubMed ID: 28589424 [No Abstract] [Full Text] [Related]
9. Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon. Burocziova M; Burdova K; Martinikova AS; Kasparek P; Kleiblova P; Danielsen SA; Borecka M; Jenikova G; Janečková L; Pavel J; Zemankova P; Schneiderova M; Schwarzova L; Ticha I; Sun XF; Jiraskova K; Liska V; Vodickova L; Vodicka P; Sedlacek R; Kleibl Z; Lothe RA; Korinek V; Macurek L Cell Death Dis; 2019 Oct; 10(11):818. PubMed ID: 31659152 [TBL] [Abstract][Full Text] [Related]
10. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nikbakht H; Panditharatna E; Mikael LG; Li R; Gayden T; Osmond M; Ho CY; Kambhampati M; Hwang EI; Faury D; Siu A; Papillon-Cavanagh S; Bechet D; Ligon KL; Ellezam B; Ingram WJ; Stinson C; Moore AS; Warren KE; Karamchandani J; Packer RJ; Jabado N; Majewski J; Nazarian J Nat Commun; 2016 Apr; 7():11185. PubMed ID: 27048880 [TBL] [Abstract][Full Text] [Related]
11. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Zhang L; Chen LH; Wan H; Yang R; Wang Z; Feng J; Yang S; Jones S; Wang S; Zhou W; Zhu H; Killela PJ; Zhang J; Wu Z; Li G; Hao S; Wang Y; Webb JB; Friedman HS; Friedman AH; McLendon RE; He Y; Reitman ZJ; Bigner DD; Yan H Nat Genet; 2014 Jul; 46(7):726-30. PubMed ID: 24880341 [TBL] [Abstract][Full Text] [Related]
12. Functionalized Macrophage Exosomes with Panobinostat and PPM1D-siRNA for Diffuse Intrinsic Pontine Gliomas Therapy. Shan S; Chen J; Sun Y; Wang Y; Xia B; Tan H; Pan C; Gu G; Zhong J; Qing G; Zhang Y; Wang J; Wang Y; Wang Y; Zuo P; Xu C; Li F; Guo W; Xu L; Chen M; Fan Y; Zhang L; Liang XJ Adv Sci (Weinh); 2022 Jul; 9(21):e2200353. PubMed ID: 35585670 [TBL] [Abstract][Full Text] [Related]
13. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner. Esfandiari A; Hawthorne TA; Nakjang S; Lunec J Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796 [TBL] [Abstract][Full Text] [Related]
14. Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients. Zajkowicz A; Butkiewicz D; Drosik A; Giglok M; Suwiński R; Rusin M Br J Cancer; 2015 Mar; 112(6):1114-20. PubMed ID: 25742468 [TBL] [Abstract][Full Text] [Related]
16. PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy. Miller PG; Sperling AS; Mayerhofer C; McConkey ME; Ellegast JM; Da Silva C; Cohen DN; Wang C; Sharda A; Yan N; Saha S; Schluter C; Schechter I; Słabicki M; Sandoval B; Kahn J; Boettcher S; Gibson CJ; Scadden DT; Stegmaier K; Bhatt S; Lindsley RC; Ebert BL Blood; 2023 Dec; 142(24):2079-2091. PubMed ID: 37595362 [TBL] [Abstract][Full Text] [Related]
17. Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis. Lou J; Hao Y; Lin K; Lyu Y; Chen M; Wang H; Zou D; Jiang X; Wang R; Jin D; Lam EW; Shao S; Liu Q; Yan J; Wang X; Chen P; Zhang B; Jin B Mol Cancer; 2020 Sep; 19(1):138. PubMed ID: 32894144 [TBL] [Abstract][Full Text] [Related]
18. Global activation of oncogenic pathways underlies therapy resistance in diffuse midline glioma. Georgescu MM; Islam MZ; Li Y; Circu ML; Traylor J; Notarianni CM; Kline CN; Burns DK Acta Neuropathol Commun; 2020 Jul; 8(1):111. PubMed ID: 32680567 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3. Pechackova S; Burdova K; Benada J; Kleiblova P; Jenikova G; Macurek L Oncotarget; 2016 Mar; 7(12):14458-75. PubMed ID: 26883108 [TBL] [Abstract][Full Text] [Related]
20. Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D. Lu X; Nguyen TA; Donehower LA Cell Cycle; 2005 Aug; 4(8):1060-4. PubMed ID: 15970689 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]